Nanobiotix (NBTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Nanobiotix (NBTX) has a cash flow conversion efficiency ratio of 0.190x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.01 Million) by net assets ($-84.48 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see NBTX market cap for the company's overall valuation and market capitalisation.
Nanobiotix - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Nanobiotix's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Nanobiotix Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nanobiotix ranked by their cash flow conversion efficiency. See Nanobiotix (NBTX) cash flow to debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Choice International Limited
NSE:CHOICEIN
|
-0.037x |
|
Zhongmin Energy Co Ltd
SHG:600163
|
0.012x |
|
Jamf Holding
NASDAQ:JAMF
|
0.083x |
|
Five-Star Business Finance Limited
NSE:FIVESTAR
|
0.002x |
|
ALPEK S.A.B. de C.V
MX:ALPEKA
|
0.099x |
|
Telecom Argentina S.A
F:TEO
|
0.106x |
|
Wedge Industrial Co Ltd
SHE:000534
|
0.006x |
|
Golden Ocean Group Ltd
OL:GOGL
|
-0.002x |
Annual Cash Flow Conversion Efficiency for Nanobiotix (2011–2025)
The table below shows the annual cash flow conversion efficiency of Nanobiotix from 2011 to 2025. View latest Nanobiotix stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-84.48 Million | $-33.42 Million | 0.396x | +32.95% |
| 2024-12-31 | $-65.70 Million | $-19.55 Million | 0.298x | -95.60% |
| 2023-12-31 | $-1.84 Million | $-12.48 Million | 6.766x | +393.17% |
| 2022-12-31 | $-27.05 Million | $-37.10 Million | 1.372x | +223.04% |
| 2021-12-31 | $26.79 Million | $-29.87 Million | -1.115x | -185.33% |
| 2020-12-31 | $70.47 Million | $-27.54 Million | -0.391x | -101.81% |
| 2019-12-31 | $-1.91 Million | $-41.17 Million | 21.566x | +1282.07% |
| 2018-12-31 | $14.24 Million | $-25.98 Million | -1.824x | -282.51% |
| 2017-12-31 | $43.92 Million | $-20.95 Million | -0.477x | +54.61% |
| 2016-12-31 | $17.40 Million | $-18.28 Million | -1.051x | +2.47% |
| 2015-12-31 | $15.61 Million | $-16.82 Million | -1.077x | -281.37% |
| 2014-12-31 | $30.32 Million | $-8.56 Million | -0.283x | +86.84% |
| 2013-12-31 | $3.18 Million | $-6.83 Million | -2.147x | -511.35% |
| 2012-12-31 | $10.70 Million | $-3.76 Million | -0.351x | +93.33% |
| 2011-12-31 | $925.53K | $-4.87 Million | -5.265x | -- |
About Nanobiotix
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small … Read more